Botox in the Healing of Surgical Wounds of the Neck
Launched by NOVA SCOTIA HEALTH AUTHORITY · Aug 6, 2010
Trial Information
Current as of June 04, 2025
Completed
Keywords
ClinConnect Summary
Botulinum Toxin A is a toxin produced by the anaerobic bacterial species Clostridium botulinum. The toxin specifically inhibits release of the neurotransmitter Acetylcholine at synaptic junctions, thus preventing neuromuscular transmission, and inducing paralysis of the muscle.
Previous studies have indicated that tensile forces on the skin may affect the healing of a wound. These forces act against the immature collagen laid down during wound healing and may stimulate overgrowth, thereby contributing to the formation of hypertrophic scars or keloids.
Using botox to paralyse the underlyin...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • all patients referred to the ENT clinic for a thyroidectomy or parathyroidectomy
- Exclusion Criteria:
- • patients with missing information, including demographic information
- • patients lost to follow up or have been followed for less than 6 months
- • patients with known allergy to lidocaine
- * patients in whom botox would be contraindicated in:
- • known history of neuromuscular disorders (myasthenia gravis, amyotrophic lateral sclerosis, Eaton-Lambert syndrome)
- • pregnant women
- • known allergy to botox, albumin
About Nova Scotia Health Authority
The Nova Scotia Health Authority (NSHA) is a leading healthcare organization dedicated to enhancing the health and well-being of individuals and communities across Nova Scotia, Canada. As the largest provider of health services in the province, NSHA is committed to advancing clinical research and innovation through rigorous clinical trials that aim to improve patient care and outcomes. With a focus on collaboration, NSHA engages healthcare professionals, researchers, and patients to address pressing health challenges and contribute to the global body of medical knowledge. By fostering a culture of evidence-based practice and continual improvement, NSHA plays a pivotal role in shaping the future of healthcare delivery in the region.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Halifax, Nova Scotia, Canada
Patients applied
Trial Officials
Mark Taylor, FRCS
Principal Investigator
Capital District Health Authority Nova Scotia
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials